Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma

Although epidermal growth factor receptor (EGFR) is often over-expressed in soft tissue sarcoma (STS), a phase II trial using an EGFR inhibitor gefitinib showed a low response rate. This study identified a new secondary resistance mechanism of gefitinib in STS, and developed new strategies to improv...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Wang, Xiaochun, Goldstein, David, Crowe, Philip J., Yang, Mark, Garrett, Kerryn, Zeps, Nikolajs, Yang, Jia-Lin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5008301/
https://ncbi.nlm.nih.gov/pubmed/26909593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7452
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi